{
    "id": 476,
    "fullName": "EZH2 Y641S",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 Y641S lies within the SET domain of the Ezh2 protein (UniProt.org). Y641S confers a gain of function to the Ezh2 protein, as demonstrated by altered substrate specificity and increased catalytic efficiency for H3K27 trimethylation (PMID: 21190999, PMID: 21078963).",
            "references": [
                {
                    "id": 2703,
                    "pubMedId": 21078963,
                    "title": "Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21078963"
                },
                {
                    "id": 505,
                    "pubMedId": 21190999,
                    "title": "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190999"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "Y641S",
    "createDate": "05/02/2014",
    "updateDate": "09/17/2018",
    "referenceTranscriptCoordinates": {
        "id": 171530,
        "transcript": "NM_001203247",
        "gDna": "chr7:g.148811635T>G",
        "cDna": "c.1922A>C",
        "protein": "p.Y641S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6557,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6562,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GSK126 did not alter cell-cycle progression or decrease survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 reversed transcriptional silencing in human melanoma cells harboring wild-type EZH2 Y641S in culture (PMID: 26936398).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5127,
                    "pubMedId": 26936398,
                    "title": "Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6559,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 4148,
                "therapyName": "ACY-957 + GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6564,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with DZNeP resulted in a slight increase in number of dead or sub-G1 cells and accumulation of DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 2702,
                "therapyName": "DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6552,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 4144,
                "therapyName": "ACY-957",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6561,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 4147,
                "therapyName": "ACY-957 + DZNeP",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5689,
                    "pubMedId": 25605023,
                    "title": "HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 673,
            "profileName": "EZH2 Y641S",
            "profileTreatmentApproaches": [
                {
                    "id": 4592,
                    "name": "EZH2 inhibitor",
                    "profileName": "EZH2 Y641S"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171530,
            "transcript": "NM_001203247",
            "gDna": "chr7:g.148811635T>G",
            "cDna": "c.1922A>C",
            "protein": "p.Y641S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171531,
            "transcript": "XM_011515889",
            "gDna": "chr7:g.148810374T>G",
            "cDna": "c.1922A>C",
            "protein": "p.Y641S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}